interchange of vaccine products; Revaccination with different COVID-19 vaccine; Patient experienced suspected COVID-19 infection after dose two; This spontaneous case was reported by a patient and describes the occurrence of SUSPECTED COVID-19 (Patient experienced suspected COVID-19 infection after dose two), INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis.    No Medical History information was reported.   In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. In June 2022, the patient experienced SUSPECTED COVID-19 (Patient experienced suspected COVID-19 infection after dose two). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine). At the time of the report, SUSPECTED COVID-19 (Patient experienced suspected COVID-19 infection after dose two) outcome was unknown and INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) had resolved.            No concomitant medication information was provided.  On Jun-2021 patient experienced suspected COVID-19 infection (dose number in series 2) with symptoms of scratchy throat, joint pain, slight nasal congestion (head colds were worsen then this ) loss of taste and smell.  The patient had it in the mildest with no fever and no cough.  No treatment medication were provided.  Company comment:  This spontaneous case concerns a patient of unknown age and gender, with no medical history reported, who experienced the non-serious, unexpected AESI of suspected COVID-19 the year after receiving a dose of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date and event onset date were not clearly reported. Patient had previously received a dose of Jansen COVID-19 vaccine, hence interchange of vaccine products was considered as an additional event. Patient experienced scratchy throat, joint pain, slight nasal congestion, loss of taste and smell and described it as mild. It is unknown if a diagnostic test was performed. No further relevant information was available for medical reviewing. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient of unknown age and gender, with no medical history reported, who experienced the non-serious, unexpected AESI of suspected COVID-19 the year after receiving a dose of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date and event onset date were not clearly reported. Patient had previously received a dose of Jansen COVID-19 vaccine, hence interchange of vaccine products was considered as an additional event. Patient experienced scratchy throat, joint pain, slight nasal congestion, loss of taste and smell and described it as mild. It is unknown if a diagnostic test was performed. No further relevant information was available for medical reviewing. The benefit-risk relationship of mRNA-1273 is not affected by this report.